CRANFORD, N.J., Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will present at the BIO CEO and Investor Conference on February 26-27, 2024, and the Sidoti Small-Cap Virtual Conference on March 13-14, 2024. BIO CEO ...

Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial CRANFORD, N.J., Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter 2024 ended December 31, 2023. First Quarter 2024 Busine ...

FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission CRANFORD, N.J., Feb. 13, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the resubmission of the Company's Biologics License Application (BLA) to the U.S. Food a ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 27-3425913 ( ...

Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD, N.J., Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the nomination of seasoned pharmaceutical executive Robert J. Smith to its Board of Directors. The nomination of Mr. Smith is subject to shareholder ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Nevada 27-3425913 (State or other jurisdiction of (I.R.S. Employer incorporation or organi ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 27-3425913 (Stat ...

公司概况 - 公司是一家专注于开发和商业化首创重症护理产品的生物制药公司[70] 营收情况 - 公司在2023年第一季度没有实现任何营收[83] - 2023年3月31日，公司未实现任何营收[95] 研发支出 - 研发支出在2023年第一季度达到4,726,855美元，较2022年同期增加了1,274,645美元[84] - 2023年3月31日，研发费用为817万2370美元，较2022年同期的891万0059美元减少了73万7689美元[96] - Mino-Lok的研发成本增加了33万5463美元，达到了221万7748美元，主要是由于与全球临床研究组织Biorasi合作，扩大了公司的Mino-Lok试验范围[97] - Halo-Lido的研发成本增加了102万9621美元，达到了273万1098美元，主要是由于2023年3月31日的第二阶段试验成本增加[98] - I/ONTAK的研发成本在2023年第一季度为1,402,908美元，较2022年同期减少了179,663美元[87] - I/ONTAK的研发成本为283万1453美元，较2022年同期的452万0365美元减少了168万8912美元[99] - 2023财年预计研发费用将稳定，重点放在I/ONTAK的商业化上，同时完成Mino-Lok的第三阶段试验和Halo-Lido的第二阶段试验[100] 财务状况 - 总体而言，公司在2023年第一季度录得净亏损10,526,025美元，较2022年同期的净亏损7,561,054美元增加了2,964,971美元[93] - 2023年3月31日，公司的总体和行政费用为739万6137美元，较2022年同期的601万4166美元增加了138万1971美元[101] - 2023年3月31日，股权补偿费用为236万6676美元，较2022年同期的192万5602美元增加了441万074美元[103] - 2023年3月31日，利息收入为517万824美元，较上一期的利息收入63553美元增加，主要是由于利率上升[104] - 2023年3月31日，公司录得了28万8000美元的递延所得税费用，主要与其研发资产的摊销有关[106]

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 27-3425913 ( ...

P H A R M A | --- | --- | --- | |-------|------------------------------|-------| | | | | | | Citius Pharmaceuticals, Inc. | | | | | | | | Corporate Presentation | | | | | | | | Summer 2020 | | | | | | NASDAQ: CTXR Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any dire ...